Skip to main content

Table 1 Clinical characteristics of 50 patients with t-MN treated with azacitidine

From: Outcome of therapy-related myeloid neoplasms treated with azacitidine

Patient Characteristics n ( range)
Median age (years, median, range) 66 (37–84)
Sex (M/F) 28/22
ECOG PS  
0–1 46
2-3 4
Type of t-MDS/AML according to the WHO  
- AML: 16
BM-blasts 20-29% 5
BM-blasts ≥30% 11
- MDS: 34
RCMD 12
RAEB1 9
RAEB 2 13
Primary malignancy :  
- Lymphoproliferative disease 19
- Multiple myeloma 3
- Chronic myeloproliferative disease 5
- Breast cancer 6
- Urogenital 9
- Other 8
Treatment for Primary Malignancy:  
- Chemotherapy 27
- Radiotherapy 9
- RTx + CTx 14
Median latency between primary cytotoxic therapy and t-MN diagnosis (years) 6.1 (0.2-29.8)
Median value at diagnosis (range):  
- White blood cell counts (109 /L) 2.6 (0.1-26)
- Platelets (109 /L) 69.5 (5–395)
- Bone Marrow blasts (%) 13 (1–90)
- LDH (UI/L) 403 (130–2498)
Median interval between t-MN diagnosis and AZA treatment (months) 1.8 (0–39)
Response to treatment:  
- Overall response: 20 (42%)
- CR 10 (21%)
- PR 2 (4.2%)
- HI 8 (16.7%)
- Stable disease 15 (31%)
- Progression 13 (27%)
- Not evaluable 2
Median cycles number for response 3 (range 1–6)
  1. Legend: RTx: Radiotherapy ; CTx: Chemotherapy; CR: complete remission; PR: partial remission; HI: hematological improvement.